Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for entrepreneurs, about the start-up’s strategic approach to securing the right investment for phage-based technology.
  • August 7, 2018
  • Company
  • interview, investment
Dr Berwyn Clarke at REAP
Dr Berwyn Clarke at Agri-Tech East's REAP conference

Commenting on the £400,000 that was secured from angel investment, alongside other sources, Dr Clarke said: “Angel investment was chosen as a successful route for PBD Biotech’s specialised products. This was because of the specialist local networks of individuals knowledgeable about the industry, and who understood the international opportunity offered by the technology.

“There is an enormous need for a tool to better monitor and control TB and M. paratuberculosis infections in livestock and other animals, and as such there is an enormous value attachment for an accurate test like Actiphage®. In England alone, bovine TB costs taxpayers over £100 million every year.”

To read the full interview about PBD Biotech, please visit growthbusiness.co.uk

Share:

Related posts

Loading...

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!